Literature DB >> 7685143

[Clinical evaluation of the long-term treatment with chlormadinone acetate in patients with benign prostatic hypertrophy].

T Kogawa1, H Yanagiya, T Takashima, I Higashino, T Kudo, T Suzuki, T Mikuni, K Kido, A Tsukui, Y Yagihashi.   

Abstract

Fifty patients with benign prostatic hypertrophy were treated with chlormadinone acetate (CMA) at the dose of 50 mg/day for 12 months. Subjective symptoms and objective findings were evaluated before, and after 4 and 12 months of treatment. Better improvement was observed in all of the subjective symptoms and in almost all the parameters of objective findings, in proportion to the period of CMA treatment. Generally speaking, 12 months of treatment was more effective than 4 months of treatment. Two patients had impotence (4.0%). Both of them complained of side effects within 4 months after treatment, but they were not severe. In conclusion, long-term treatment of benign prostatic hypertrophy with CMA was useful.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685143

Source DB:  PubMed          Journal:  Hinyokika Kiyo        ISSN: 0018-1994


  2 in total

1.  Renewing intimacy: advances in treating erectile dysfunction postprostatectomy.

Authors:  Herbert Lepor; Andrew McCullough; Jason D Engel
Journal:  Rev Urol       Date:  2008

2.  The effects of chlormadinone acetate on lower urinary tract symptoms and erectile functions of patients with benign prostatic hyperplasia: a prospective multicenter clinical study.

Authors:  Kiyohide Fujimoto; Yoshihiko Hirao; Yasuo Ohashi; Yasuhiro Shibata; Kohzo Fuji; Hidenori Tsuji; Katsuhito Miyazawa; Mikinobu Ohtani; Ryoji Furuya; Eitetsu Boku
Journal:  Adv Urol       Date:  2013-05-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.